This global role will lead the medical evidence strategy for the RSV adult vaccines asset, focusing on vaccine effectiveness and burden studies.
Base: $230,900.00 - $384,800.00; Bonus/Equity: 25.0% bonus target, eligibility for share-based long term incentive; Benefits: Comprehensive and generous benefits and programs
Must-have
Nice-to-have
Permanent work authorization